Repositorio Dspace

Listar por tema "Immune Checkpoint Inhibitors/therapeutic use"

Listar por tema "Immune Checkpoint Inhibitors/therapeutic use"

Ordenar por:Orden:Resultados:

  • Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801 
    Espinosa, Enrique; Berciano-Guerrero, Miguel-Ángel; Muñoz-Couselo, Eva; Puertolas, Teresa; Manzano, José-Luis; Soria, Ainara; Ayala-de-Miguel, Pablo; Crespo, Guillermo; Gutiérrez-Sanz, Lourdes; Cerezuela-Fuentes, Pablo; Aguado-de-la-Rosa, Carlos; Majem, Margarita; García-Castaño, Almudena; Berrocal, Alfonso; García-Arroyo, Francisco-Ramon; Rodríguez-de-la-Borbolla, María; Bellido, Lorena; Medina-Martínez, Javier; Fernández, Luis-Antonio; Marín-Carnicero, Alfonso; López-Castro, Rafael; Bujosa-Rodríguez, Aida; Lecumberri, María-José; Villa-Guzmán, José-Carlos; Campos-Balea, Begoña; Rodríguez, Joaquin-Fra; Valdivia-Bautista, Javier; Navarro-Pérez, Víctor; Mujika, Karmele; Corral-Subias, Mónica; Hernández, Berta; Martín-Algarra, Salvador; Márquez-Rodas, Iván (SPRINGER INT PUBL AG, 2025-11-28)
    PURPOSE: Anti-PD-1-based immunotherapy and targeted therapies (TT) are the current standard of care for patients with advanced melanoma. However, some patients die in less than a year from diagnosis and others become ...
  • SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023) 
    Rivera, Fernando; Longo-Muñoz, Federico; Martín-Richard, Marta; Richart, Paula; Alsina, María; Carmona-Bayonas, Alberto; Custodio, Ana-Belén; Fernández-Montes, Ana; Gallego, Javier; Fleitas-Kanonnikoff, Tania (Springer Int Publ Ag, 2024-11)
    Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh ...